Eisai (OTC: ESALY)
Some price data may be temporarily unavailable.
Eisai Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Eisai Company Info
Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.
News & Analysis
The 3 Best Obesity-Drug Stocks to Buy in 2017
Looking for obesity-drug stocks to buy? Check out the biggest and best: Eisai, Novo Nordisk, and Roche.
Why Arena Pharmaceuticals Stock Is Surging Higher Today
The biopharma's shares soared by double-digits Wednesday on a strong Q4 earnings release.
How Marijuana Could Play a Role in Alzheimer's Disease Treatment
Experts think they know how to treat Alzheimer's disease, but it won't be easy. Here's how cannabis could help.
How to Ride the Next Wave of Potential Alzheimer's Drugs
See how soon-to-be-released BACE inhibitor safety data could play a huge role in the future of Alzheimer's drug development.
5 Freakishly Expensive Cancer Drugs
Prices for cancer medications are soaring.
Is Arena or VIVUS the Better Obesity Drug Stock?
Arena and VIVUS have had a tough year. Is it finally time to take the contrarian view and consider them worthy investments?
Today’s Top Biotech Stories: Xoma, Biogen, Agenus, and GSK
Xoma, Biogen, Agenus, and GSK could all loom large in health care headlines this morning.
10 Countries With the Longest Life Expectancy
These are the 10 countries with the longest life expectancy. See what factors have allowed their citizens to live longer as well as how you might be able to benefit from their longevity.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.